search
Back to results

Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects

Primary Purpose

Obesity, Metabolic Disease

Status
Recruiting
Phase
Not Applicable
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Kale supplement
Peas supplement
Sponsored by
Chair for Biomarkers of Chronic Diseases
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Obesity focused on measuring Kale supplement, Microbiome, Obesity, Endotoxin

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Obese (BMI 30-40Kg/m2 and above)
  • Aged 18-40 years
  • Saudi nationality
  • Female

Exclusion Criteria:

  • Age under 18 or above 40 years
  • Any medical/endocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome)
  • Those with chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulatory like cyclosporine, azathioprine; severe depression or any psychiatric illness, claustrophobia or needle phobia.
  • Males
  • Expatriates

Sites / Locations

  • Community Health Department, Applied Medical Sciences, King Saud UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Experimental Group: Kale

Placebo Group: Green Peas

Arm Description

This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.

This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.

Outcomes

Primary Outcome Measures

Study the acute-term effects of freeze-dried Kale in lipid profile of obese, non-T2DM women
Differences in characteristics of total cholesterol (mmol/l), hdl-cholesterol (mmol/l), ldl-cholesterol (mmol/l) and triglycerides (mmol/l) at baseline and subsequent follow ups.
Study the medium-term effects of freeze-dried Kale in lipid profile of obese, non-T2DM women
Differences in characteristics of total cholesterol (mmol/l), hdl-cholesterol (mmol/l), ldl-cholesterol (mmol/l) and triglycerides (mmol/l) at baseline and subsequent follow ups.

Secondary Outcome Measures

Study the acute and medium term effects of Kale Superfood on BMI
Differences in body mass index (BMI, kg/m2) at baseline and subsequent follow-ups
Study the acute and medium term effects of Kale Superfood on glucose levels
Differences in fasting glucose (mmol/l), at baseline and subsequent follow-ups
Study the acute and medium term effects of Kale Superfood on alanine aminotransferase levels
Differences in alanine aminotransferase (ALT, U/L)at baseline and subsequent follow-ups
Study the acute and medium term effects of Kale Superfood on aspartate aminotransferase levels
Differences in aspartate aminotransferase (AST, U/L) at baseline and subsequent follow-ups
Study the acute and medium term effects of Kale Superfood on HbA1c levels
Differences in Hemoglobin A1c (Hba1C, %), at baseline and subsequent follow-ups
Study the acute and medium term effects of Kale Superfood on insulin levels
Differences in insulin (IU/ml) at baseline and subsequent follow-ups
Study the acute and medium term effects of Kale Superfood on C-peptide levels
Differences in C-peptide levels (nmol/L) at baseline and subsequent follow-ups

Full Information

First Posted
April 18, 2021
Last Updated
January 13, 2022
Sponsor
Chair for Biomarkers of Chronic Diseases
Collaborators
King AbdulAziz City for Science and Technology
search

1. Study Identification

Unique Protocol Identification Number
NCT04904601
Brief Title
Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects
Official Title
Acute and Medium Effects of Freeze-dried Kale to go, New Superfood Supplement to Reduce Metabolic Risk in Saudi Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
January 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 15, 2021 (Actual)
Primary Completion Date
February 26, 2022 (Anticipated)
Study Completion Date
December 27, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chair for Biomarkers of Chronic Diseases
Collaborators
King AbdulAziz City for Science and Technology

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Whilst obesity represents a key risk factor for the development of metabolic disease and further premature mortality, the actual type of diet may provide the 'primary insults' for inflammation affecting systemic health in the pre-diabetic state such as obesity. Specifically, previous data indicate that a high-fat diet and/or unfavorable systemic lipid profiles can impair metabolic health which may occur via inflammatory mechanisms. The study aims to conduct a randomized interventional dietary trial with Freeze-dried Kale, as a superfood, to reduce inflammation and improve lipid profile in patients with obesity. These studies will analyze the effects of this superfood on metabolic changes among obese and non-obese Saudi women. Our hypothesis is the inclusion of Brassica into the daily diet will significantly improve metabolic health, microbiota composition, lower inflammatory insults (inflammasome), and lower microbial translocation, with resulting improvements in metabolic health. The team, therefore, proposes to examine the impact of the superfood kale on lipid function (acute and medium-term) over a 4 week dietary intervention period to assess the influence on metabolic change and biomarker changes. The team intends to utilize the expertise from a broad spectrum of specialists from plant biologists, clinical and allied health care professionals, and translational scientists, to provide a unique holistic insight into the role of nutrition for metabolic health benefits in human participants. These studies will provide us with the capacity to use a directly applicable dietary supplement, freeze-dried Kale, to improve the health of people metabolically. As this is a natural product, this will have the capability to reach the market much quicker and advance research at a much faster pace. This dietary supplement will also provide an additional measure to improve the health across the general public not just those at increased risk of disease to help provide another way to improve health among Saudis.
Detailed Description
Subjects Selection: For this study we will recruit a total of 100 obese age matched non-diabetic Saudi women, (age 18-40 years; BMI 30-40Kg/m2) through college clinics in applied medical sciences college, KSU. The study participants exclusion criteria in brief: age under 18 or above 40 years, any medical/endocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome); chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulatory like cyclosporine, azathioprine; severe depression or any psychiatric illness, claustrophobia or needle phobia. Sample and Data Collections: Anthropometry and body composition as well as biochemical data will be undertaken for all visits, including blood, urine and stool collection. Serum will be collected all patients for later analysis. All samples collected will be stored appropriately for biochemical analysis within the Bio-Bank facilities, in the Chair for Biomarkers of Chronic Diseases in King Saud University. All samples will be stored at -80oC following the appropriate protocol extraction methods. Intervention: Participants will be randomized to give either Kale (blanched freeze dried Kale) group1 or placebo (Blanched Freeze dried Peas) group2. The supplements will be given as one scoop of powder of (Kale or Green Peas) three times a day for a total of 10g/day. The follow up will be for 6 week intervention. After visit 2 will be washout period for 2 weeks, to study acute and medium effects, followed by a cross-over between the groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Metabolic Disease
Keywords
Kale supplement, Microbiome, Obesity, Endotoxin

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Kale (blanched freeze-dried Kale) group 1 (N=50 adult obese Saudi women) Placebo (Blanched Freeze-dried Peas) group 2 (N=50 adult obese Saudi women)
Masking
ParticipantInvestigator
Masking Description
Both the participant and investigator are blinded. Randomization and blinding will be done by a third party.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Group: Kale
Arm Type
Active Comparator
Arm Description
This group will be given one scoop of powder of (Kale) three times a day for a total of 10g/day for 6 weeks.
Arm Title
Placebo Group: Green Peas
Arm Type
Placebo Comparator
Arm Description
This group will be given one scoop of powder of (Green Peas) three times a day for a total of 10g/day for 6 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Kale supplement
Intervention Description
Kale (blanched freeze-dried Kale) group1
Intervention Type
Dietary Supplement
Intervention Name(s)
Peas supplement
Intervention Description
placebo (Blanched Freeze-dried Peas) group2
Primary Outcome Measure Information:
Title
Study the acute-term effects of freeze-dried Kale in lipid profile of obese, non-T2DM women
Description
Differences in characteristics of total cholesterol (mmol/l), hdl-cholesterol (mmol/l), ldl-cholesterol (mmol/l) and triglycerides (mmol/l) at baseline and subsequent follow ups.
Time Frame
2 weeks
Title
Study the medium-term effects of freeze-dried Kale in lipid profile of obese, non-T2DM women
Description
Differences in characteristics of total cholesterol (mmol/l), hdl-cholesterol (mmol/l), ldl-cholesterol (mmol/l) and triglycerides (mmol/l) at baseline and subsequent follow ups.
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Study the acute and medium term effects of Kale Superfood on BMI
Description
Differences in body mass index (BMI, kg/m2) at baseline and subsequent follow-ups
Time Frame
6 weeks
Title
Study the acute and medium term effects of Kale Superfood on glucose levels
Description
Differences in fasting glucose (mmol/l), at baseline and subsequent follow-ups
Time Frame
6 weeks
Title
Study the acute and medium term effects of Kale Superfood on alanine aminotransferase levels
Description
Differences in alanine aminotransferase (ALT, U/L)at baseline and subsequent follow-ups
Time Frame
6 weeks
Title
Study the acute and medium term effects of Kale Superfood on aspartate aminotransferase levels
Description
Differences in aspartate aminotransferase (AST, U/L) at baseline and subsequent follow-ups
Time Frame
6 weeks
Title
Study the acute and medium term effects of Kale Superfood on HbA1c levels
Description
Differences in Hemoglobin A1c (Hba1C, %), at baseline and subsequent follow-ups
Time Frame
6 weeks
Title
Study the acute and medium term effects of Kale Superfood on insulin levels
Description
Differences in insulin (IU/ml) at baseline and subsequent follow-ups
Time Frame
6 weeks
Title
Study the acute and medium term effects of Kale Superfood on C-peptide levels
Description
Differences in C-peptide levels (nmol/L) at baseline and subsequent follow-ups
Time Frame
6 weeks

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Women only
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Obese (BMI 30-40Kg/m2 and above) Aged 18-40 years Saudi nationality Female Exclusion Criteria: Age under 18 or above 40 years Any medical/endocrine problem that could affect energy expenditure (e.g. thyroid problems, Cushing's syndrome) Those with chronic inflammatory disorders like rheumatoid arthritis, or long term use of steroids or other immunomodulatory like cyclosporine, azathioprine; severe depression or any psychiatric illness, claustrophobia or needle phobia. Males Expatriates
Facility Information:
Facility Name
Community Health Department, Applied Medical Sciences, King Saud University
City
Riyadh
ZIP/Postal Code
11451
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dara Al-Disi, PhD
Phone
+966548403333
Email
daldisi@ksu.edu.sa
First Name & Middle Initial & Last Name & Degree
Dara Al-Disi, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects

We'll reach out to this number within 24 hrs